BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21606353)

  • 1. Platelet gene therapy improves hemostatic function for integrin alphaIIbbeta3-deficient dogs.
    Fang J; Jensen ES; Boudreaux MK; Du LM; Hawkins TB; Koukouritaki SB; Cornetta K; Wilcox DA
    Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9583-8. PubMed ID: 21606353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia.
    Fang J; Hodivala-Dilke K; Johnson BD; Du LM; Hynes RO; White GC; Wilcox DA
    Blood; 2005 Oct; 106(8):2671-9. PubMed ID: 15972454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Insights Into the Treatment of Glanzmann Thrombasthenia.
    Poon MC; Di Minno G; d'Oiron R; Zotz R
    Transfus Med Rev; 2016 Apr; 30(2):92-9. PubMed ID: 26968829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoprotein IIb Leu214Pro mutation produces glanzmann thrombasthenia with both quantitative and qualitative abnormalities in GPIIb/IIIa.
    Grimaldi CM; Chen F; Wu C; Weiss HJ; Coller BS; French DL
    Blood; 1998 Mar; 91(5):1562-71. PubMed ID: 9473221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (alphaIIbbeta3) integrin receptor locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype.
    Ruiz C; Liu CY; Sun QH; Sigaud-Fiks M; Fressinaud E; Muller JY; Nurden P; Nurden AT; Newman PJ; Valentin N
    Blood; 2001 Oct; 98(8):2432-41. PubMed ID: 11588040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glanzmann thrombasthenia: state of the art and future directions.
    Nurden AT; Pillois X; Wilcox DA
    Semin Thromb Hemost; 2013 Sep; 39(6):642-55. PubMed ID: 23929305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A unique phenotype of acquired Glanzmann thrombasthenia due to non-function-blocking anti-αIIbβ3 autoantibodies.
    Akuta K; Kashiwagi H; Yujiri T; Nishiura N; Morikawa Y; Kato H; Honda S; Kanakura Y; Tomiyama Y
    J Thromb Haemost; 2019 Jan; 17(1):206-219. PubMed ID: 30388316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C560Rβ3 caused platelet integrin αII b β3 to bind fibrinogen continuously, but resulted in a severe bleeding syndrome and increased murine mortality.
    Fang J; Nurden P; North P; Nurden AT; Du LM; Valentin N; Wilcox DA
    J Thromb Haemost; 2013 Jun; 11(6):1163-71. PubMed ID: 23551977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel Pro126His beta propeller mutation in integrin alphaIIb causes Glanzmann thrombasthenia by impairing progression of pro-alphaIIbbeta3 from endoplasmic reticulum to Golgi.
    Shen WZ; Ding QL; Jin PP; Wang XF; Jiang YZ; Li SM; Wang HL
    Blood Cells Mol Dis; 2009; 42(1):44-50. PubMed ID: 18976939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classification of Iranian patients with Glanzmann's Thrombasthenia using a flow cytometric method.
    Farsinejad A; Abolghasemi H; Kazemi A; Aghaiipour M; Hadjati E; Faranoush M; Jazebi M; Ala F
    Platelets; 2011; 22(5):321-7. PubMed ID: 21526886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction of a large animal model of type I Glanzmann's thrombasthenia by nonmyeloablative bone marrow transplantation.
    Niemeyer GP; Boudreaux MK; Goodman-Martin SA; Monroe CM; Wilcox DA; Lothrop CD
    Exp Hematol; 2003 Dec; 31(12):1357-62. PubMed ID: 14662345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained engraftment post bone marrow transplant despite anti-platelet antibodies in Glanzmann thrombasthenia.
    Flood VH; Johnson FL; Boshkov LK; Thomas GA; Nugent DJ; Bakke AC; Nicholson HS; Tilford D; Brown MP; Godder KT
    Pediatr Blood Cancer; 2005 Dec; 45(7):971-5. PubMed ID: 15768382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two genetic defects in alphaIIb are associated with type I Glanzmann's thrombasthenia in a Great Pyrenees dog: a 14-base insertion in exon 13 and a splicing defect of intron 13.
    Lipscomb DL; Bourne C; Boudreaux MK
    Vet Pathol; 2000 Nov; 37(6):581-8. PubMed ID: 11105947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural history of platelet antibody formation against αIIbβ3 in a French cohort of Glanzmann thrombasthenia patients.
    Fiore M; Firah N; Pillois X; Nurden P; Heilig R; Nurden AT
    Haemophilia; 2012 May; 18(3):e201-9. PubMed ID: 22250950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glanzmann Thrombasthenia in Pakistani Patients: Identification of 7 Novel Pathogenic Variants in the Fibrinogen Receptor αIIbβ3.
    Siddiqi MYJ; Boeckelmann D; Naz A; Imran A; Ahmed S; Najmuddin A; Zieger B
    Cells; 2023 Jan; 12(2):. PubMed ID: 36672149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should studies on Glanzmann thrombasthenia not be telling us more about cardiovascular disease and other major illnesses?
    Nurden AT
    Blood Rev; 2017 Sep; 31(5):287-299. PubMed ID: 28395882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NLRP3 regulates platelet integrin αIIbβ3 outside-in signaling, hemostasis and arterial thrombosis.
    Qiao J; Wu X; Luo Q; Wei G; Xu M; Wu Y; Liu Y; Li X; Zi J; Ju W; Fu L; Chen C; Wu Q; Zhu S; Qi K; Li D; Li Z; Andrews RK; Zeng L; Gardiner EE; Xu K
    Haematologica; 2018 Sep; 103(9):1568-1576. PubMed ID: 29794149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Megakaryocyte-targeted synthesis of the integrin beta(3)-subunit results in the phenotypic correction of Glanzmann thrombasthenia.
    Wilcox DA; Olsen JC; Ishizawa L; Bray PF; French DL; Steeber DA; Bell WR; Griffith M; White GC
    Blood; 2000 Jun; 95(12):3645-51. PubMed ID: 10845892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissociation between fibrinogen and fibrin interaction with platelets in patients with different subtypes of Glanzmann's thrombasthenia: studies in an ex vivo perfusion chamber model.
    Hainaud P; Brouland JP; André P; Simoneau G; Bal Dit Sollier C; Drouet L; Caen J; Bellucci S
    Br J Haematol; 2002 Dec; 119(4):998-1004. PubMed ID: 12472580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunisation against αIIbβ3 and αvβ3 in a type 1 variant of Glanzmann's thrombasthenia caused by a missense mutation Gly540Asp on β3.
    Wihadmadyatami H; Röder L; Berghöfer H; Bein G; Heidinger K; Sachs UJ; Santoso S
    Thromb Haemost; 2016 Aug; 116(2):262-71. PubMed ID: 27098940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.